AHA 2019 | RECOVERY: Early Surgery in Asymptomatic Severe Aortic Stenosis

This small randomized study heated the debate about when to intervene aortic stenosis (AS). Putting off surgical valve replacement (SAVR) in patients with asymptomatic AS and waiting for symptom onset with conservative care increased periprocedural risk and all cause cardiovascular death.  

AHA 2019 | RECOVERY: Cirugía precoz en estenosis aórtica severa asintomática

This study presented by Dr Duk-Hyun Kang during AHA 2019 scientific sessions (simultaneously published in NEJM) supports the idea of preventive valve replacement in asymptomatic patients with severe aortic stenosis.

The RECOVERY randomized 145 asymptomatic patients with severe AS (valve area ≤0.75 cm² and peak systolic velocity ≥ 4.5 m/seg or mean gradient ≥ 50 mmHg) of 4 hospitals in Korea to early surgery (within 2 months) vs waiting for symptom onset with conventional care.

 


Read also: AHA 2019 | GALILEO-4D: Rivaroxaban in the Prevention of Post TAVR Valve Thickening and Thrombosis.


Surgery was successful in the 72 patients who received it, with 0 mortality. 74% of patients under conventional care wound up receiving TAVR or SAVR for symptom onset at follow-up (mean time between randomization and symptom onset was 700 days). This group showed no periprocedural mortality as well. 

After over 6 years, cardiovascular mortality was significantly lower in the early intervention group (1% vs 15%; HR 0.09; CI 95% 0.01-0.67). All-cause mortality also resulted lower (7% vs 21%; HR 0.33; CI 95% 0.12-0.90).

Valvulopathy definition values were very strict. Stenosis was quite severe, which is why many patients were most likely self-limited rather than asymptomatic, in addition to having very low surgical risk. 

As regards modifying guideline recommendations, we still ought to wait for the outcomes of ongoing randomized studies such as the EARLY TAVR.

recovery-aha2019

Original Title: Early surgery or conservative care for asymptomatic aortic stenosis.

Reference: Kang D-H et al. Presentado en las sesiones científicas del congreso AHA 2019 y publicado simultáneamente en NEJM.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...